UltraSight raises $24 million in Series B2 financing to expand its AI-guided cardiac workflow platform across U.S. health systems, led by Alive HealthTech Growth Fund.
Connecticut InnovationsStar51 CapitalAlive Health Tech Growth FundE Health VenturesMayo Clinic VenturesNyuIron NationeHealth VenturesAlive HealthTech Growth FundDeep Insight
Description
UltraSight has successfully raised $24 million in Series B2 funding to support the commercial expansion of its Echosystem platform in the United States. This financing aims to develop high-value workflows for critical care settings and facilitate strategic collaborations. The funding was led by Alive HealthTech Growth Fund with participation from several other investors, including existing partners. This capital will help UltraSight enhance its market presence and improve cardiac imaging workflows.
Company Information
Company
UltraSight
Location
Boston, Massachusetts, United States
About
UltraSight is a leader in AI-guided cardiac workflows, focused on enhancing cardiac care through its Echosystem platform. The company aims to facilitate real-time imaging decisions that significantly impact patient management in critical care and cardiovascular settings. UltraSight combines proprietary AI innovations with clinical evidence to support broader cardiac imaging workflows. It is committed to improving access to high-quality cardiac ultrasound for better patient outcomes.
Fundz sees it the moment UltraSight raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
BostonBiotechnologyHealth CareArtificial IntelligenceMedicalMedical DeviceMachine LearningHealth Diagnostics